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Dynamic coronary vasoconstriction may play a role in coronary 
artery reocclusion after successful thrombolysis. The effect of 
nitroglycerin on the thrombolytic effects of recombinant tissue· 
type plasminogen activator (rt·PA) was examined in dogs with an 
electrically induced occlusive coronary artery thrombus. Eleven 
dogs were randomly given rt·PA alone and seven rt·PA with 
nitroglycerin. The dose of rt·PA was 0.75 mg/kg body weight 
given over 20 min and the dose of nitroglycerin was 125 pg/min 
for 40 min. 
The reperfusion rate in the dogs given rt·PA alone was 73% (8 
of 11 dogs) and that in the rt·PA plus nitroglycerin group was 57% 
(four of seven dogs) (p = NS). The time to thrombolysis (or 
reperfusion) in dogs receiving rt·PA plus nitroglycerin was 70% 
greater than in those receiving rt·PA alone (means ± 
SD/29.8 ± 9.9 versus 17.6 ± 5.9 min, p < 0.02), and the duration 
of reperfusion much shorter (11 ± 17 versus 42 ± 16 min, p < 
0.02). Peak coronary blood flow after reperfusion in dogs receiv· 
ing rt·PA plus nitroglycerin was also less than in those receiving 
rt·PA alone (36 ± 52 versus 63 ± 20 mllmin, p < 0.02). 
Reocclusion occurred in all dogs given rt·PA with nitroglycerin 
and in six of eight given rt·PA alone (p = NS). 
An occlusive thrombus in the atherosclerotic coronary ar· 
tery is believed to be the precipitating factor in the genesis of 
unstable angina and acute myocardial infarction in almost all 
patients (1-3). Accordingly, therapy of such patients in· 
cludes use of thrombolytic agents such as streptokinase or 
tissue·type plasminogen activator (rt·PA) (4-7). Antiplatelet 
agents (8,9) and anticoagulants (0) are also widely used. in 
addition to thrombolytic therapy, to prevent recurrence of 
thrombus formation. 
In vivo thrombosis is associated with evidence of platelet 
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Plasma concentrations of rt·PA were lower when nitroglycerin 
was given with rt·PA alone (427 ± 279 versus 1,471 ± 600 ng/ml, 
p < 0.01). In addition, whole blood platelet aggregation decreased 
significantly with administration of rt·PA alone, but not with 
administration of rt·PA with nitroglycerin (0.23 ± 0.57 and 
5.26 ± 6.23 n, respectively, p < 0.02). Peripheral blood platelet 
count decreased during thrombus formation in all dogs; with 
administration of rt·PA alone, platelet counts stabilized but 
continued to decrease with concurrent administration of nitroglyc· 
erin with rt·PA (mean platelet counts at the end of rt·PA infusion 
7.23 ± 1.68 and 4.78 ± 3.00 x 10s/ml, respectively, p < 0.02), 
suggesting continued sequestration of platelets in the intracoro· 
nary thrombus. In four additional dogs nitroglycerin was given 
after rt·PA·induced thrombolysis, but nitroglycerin failed to 
sustain coronary artery reperfusion. 
This study shows that 1) nitroglycerin given concurrently with 
rt·PA may have a detrimental effect on the thrombolytic potential 
of rt·PA, probably because of the reduction in plasma t·PA 
concentrations, and 2) nitroglycerin given after rt·PA-induced 
thrombolysis does not prevent coronary artery reocclusion. 
(J Am Coll CardioI1991;17:805-11) 
activation and release of platelet products in the systemic 
circulation (1). Thrombolysis also is accompanied by the 
release of large amounts of thromboxane A2 (12), presum-
ably because of intense platelet activation at the site of initial 
thrombus. Thromboxane A2 exerts a potent vasoconstrictor 
influence on coronary artery tone (13). Accordingly, throm· 
bolytic therapy is followed by the use of agents that inhibit 
platelet activity and induce vasodilation. In animal models of 
occlusive intracoronary thrombosis, the efficacy of throm· 
bolytic therapy is enhanced by administration of thrombox-
ane A2 synthetase inhibitors (14), prostacyclin (15), throm-
bin inhibitors (16) or heparin (15). However, recent studies 
(17.18) reveal a reduction in the thrombolytic efficacy of 
rt-PA when a prostacyclin analog, iloprost, is given concur-
rently. This reduction in the thrombolytic potential is be· 
lieved to be due to a decrease in plasma rt-PA concentration 
secondary to increased hepatic flow and rt-PA catabolism. 
Because of its potent coronary vasodilator effects, intra· 
venous nitroglycerin is an important therapeutic agent in 
patients with acute myocardial ischemia (19). Although 
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nitroglycerin has not been shown to influence long-term 
survival, its efficacy in the relief of angina is unquestioned. 
Because many patients with acute myocardial infarction are 
given thrombolytic therapy in conjunction with intravenous 
nitroglycerin (I8), we studied the effects of nitroglycerin on 
the thrombolytic potential of rt-PA in a canine model of 
coronary artery thrombosis. 
Methods 
Experimental production of coronary artery thrombosis. 
Twenty-two mongrel dogs of either gender (average weight 
21 kg) were anesthetized with pentobarbital sodium 
(30 mg/kg), intubated, and placed on positive pressure ven-
tilation using a respirator (Harvard Apparatus). A thoracot-
omy was performed in the fifth left intercostal space and the 
heart was suspended in a pericardial cradle. The left anterior 
descending coronary artery was isolated distal to the first 
diagonal branch. An ultrasonic Doppler flow probe (Chrystal 
Biotech) was placed on the artery for measurement of 
coronary blood flow. An intracoronary thrombus was in-
duced using the technique initially described by Romson and 
coworkers (14,15,20) and subsequently used by us (18,21,22) 
and others (23). Briefly, the left anterior descending artery 
was gently rubbed to disrupt the endothelium distal to the 
flow probe. A silver-coated copper wire with a 25 gauge 
needle tip (approximately 4 mm) bent 90° was inserted distal 
to the flow probe into the coronary artery and pulled back to 
ensure contact of the electrode with the intimal surface of 
the vessel. This electrode was connected in series with a 
250,000 n variable resistor to the anode (positive terminal) of 
a 9 V nickle-cadmium battery. The cathode (negative termi-
nal) was secured to subcutaneous tissue. In all dogs an 
external plastic occluder was placed on the left anterior 
descending artery distal to the flow probe and electrode to 
reduce peak reactive hyperemia after 10 s of total occlusion 
by about 50%. The thrombus formation was initiated with 
passage of direct current (100 p.,A) through the intracoronary 
electrode until coronary blood flow was zero for at least 
30 min with the electric current turned off and the plastic 
occluder removed. Catheters were inserted into both femo-
ral veins, advanced into the inferior vena cava and used for 
drug infusion and collection of blood samples. 
Hemodynamic measurements. In addition to continuous 
measurement of coronary blood flow, ascending aortic pres-
sure was measured by inserting a catheter-tip pressure 
transducer (Millar) into a carotid artery and advancing it to 
the aortic root. Heart rate was calculated from lead II of the 
electrocardiogram. The recordings were made on a Honey-
well multichannel recorder. 
Administration of rt·PA and nitroglycerin. After the in 
situ intracoronary thrombus was fully occlusive as indicated 
by zero blood flow with the electric current on, the external 
occluder was gradually removed and the current was 
abruptly turned off. The dog was given intravenous normal 
saline solution for 30 min and the stability of thrombus (lack 
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of spontaneous dissolution) was confirmed. Thereafter, 11 
dogs were given rt-PA (0.75 mg/kg body weight over 20 min) 
alone and 7 dogs were given rt-PA (0.75 mg/kg over 20 min) 
plus nitroglycerin (125 p.,g/min for 40 min). The rt-PA and 
nitroglycerin were given through different ports. Nitroglyc-
erin was infused for 40 min to induce coronary vasodilation 
over a prolonged period in case rt-PA caused thrombolysis. 
After the drugs were administered the dogs were observed 
for 1 h for evidence of coronary reocclusion. Lidocaine, 
20 mg each time, was administered intravenously as neces-
sary, to control ventricular arrhythmias during reperfusion. 
In four other dogs nitroglycerin (125 p.,g/min for 
40 min) was given after restoration of coronary blood flow 
with rt-PA to investigate if nitroglycerin prevented coronary 
reocclusion. The dose of nitroglycerin (125 p.,g/min) was 
chosen on the basis of preliminary experiments in which this 
dose caused a decrease of 15% to 20% in mean arterial 
pressure, with little effect on coronary blood flow. Larger 
doses caused marked reductions in mean arterial pressure 
and coronary blood flow. 
Measurement of plasma t-PA levels. Samples of periph-
eral venous blood were collected in sterile disposable plastic 
syringes (Becton-Dickinson) transferred into polypropylene 
tubes and immediately placed on ice. The test tubes con-
tained 0.5 ml of indomethacin (30 p.,M) and ethylenediamine 
tetraacetic acid (EDTA. 4.5 mM), to which 5 ml of blood was 
added. Blood samples were collected before thrombus for-
mation, after thrombus formation and at the end of rt-PA 
infusion. Blood samples were immediately centrifuged at 
1.500 g for 10 minutes; plasma samples were stored at - 70°C 
for measurement of t-PA. which was completed within 4 
weeks of blood collection. 
Plasma t-PA levels were measured by the enzyme-linked 
immunosorbent assay method (18). This technique measures 
both free t-PA and circulating t-PA/inhibitor complex. We 
used the double antibody principle, which is unique for its 
design in using quenching and normal antibodies as a control 
for t -PA specificity. This method allows one to rule out 
false-positive results when measuring t-PA antigen in test 
samples. Maximal sensitivity of this assay is 0.07 ng 
t-PAlmI. which allows for considerable dilution if necessary. 
Platelet counts and platelet aggregation studies. To deter-
mine the effects of administration of rt-PA and rt-PA plus 
nitroglycerin on platelet counts and platelet aggregation in 
dogs with coronary thrombosis, peripheral venous blood 
was collected in 3.8% sodium citrate (9: 1, vol/vol). Platelet 
counts in peripheral venous blood were measured in a 
hemacytometer before thrombus formation, upon formation 
of a stable thrombus and at the end ofrt-PA infusion. Platelet 
aggregation in whole blood (diluted 1: 1 with normal saline 
solution) was determined by impedance aggregometry using 
a whole blood platelet aggregometer (model 540, Chronolog 
Corp.) (18,24). The stimulus for whole blood platelet aggre-
gation was adenosine diphosphate (ADP. 10 p.,M). 
To determine the direct effects of rt-PA on whole blood 
platelet aggregation in vitro, canine peripheral venous blood 
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Table 1. Thrombolytic Effects of rt-PA With and Without 
Nitroglycerin in 18 Dogs 
Without With 
Nitroglycerin Nitroglycerin 
(n = 11) (n = 7) 
Prethrombus CBF (ml/min) 27 ± 9 28 ± 9 
Time to zero flow (min) 39 ± 23 41 ± 28 
Time to infusion (min) 38 ± 3 36 ± 4 
Reperfusion rate (%) 73% 57% 
Time to reflow (min) 17.6 ± 5.9 29.8 ± 9.9* 
Duration of reflow (min) 42.2 ± 16.0 11.0 ± 17.4* 
Peak restored CBF (ml/min) 63 ± 20 36 ± 52* 
Restored CBF (% of 262 ± 47 156 ± 242t 
prethrombus flow) 
Reocclusion rate (%) 75 100 
*p < 0.02 versus rt-PA without nitroglycerin; tp < 0.05 versus rt-PA 
without nitroglycerin. CBF = coronary blood flow. Data are mean values ± 
SO. 
was collected in 3.8% sodium citrate (9/1, vollvol). The 
blood was diluted 1:1 with 0.9% saline solution and incu-
bated with varying concentrations of rt-PA for 5 to 10 min. 
The stimulus for platelet aggregation in these in vitro studies 
was also ADP 10 jlM. 
Agents used. Nitroglycerin (Parke Davis) was dissolved 
in saline solution, and subsequent dilutions were made just 
before its use; rt-PA was produced by recombinant DNA 
technology by Genentech, Inc. and was supplied in vials 
containing 50 mg of pure rt-PA. 
Data analysis. Data were analyzed with regard to the 
coronary blood flow at rest, time to zero flow, time from the 
formation of thrombus to the infusion of rt-PA, time to 
restoration of flow, and maximal coronary blood during 
reperfusion and duration of reflow. Frequency of thrombol-
ysis and reocclusion were analyzed by the Fisher exact test. 
Effects of thrombosis and of thrombolytic regimen on rt-PA, 
peripheral blood platelet counts, and platelet aggregation 
levels were compared by Student's t test. All values are 
expressed as mean ± SD. 
Results 
Comparative thrombolytic effects of rt·PA and rt·PA plus 
nitroglycerin (Table 1). The rt-PA was given alone in 11 dogs 
and with nitroglycerin in seven. In the two groups of dogs 
before formation of occlusive thrombus, mean coronary 
blood flow was similar (27 ± 9 and 28 ± 9 mllmin, p = NS). 
Mean time to thrombus formation was also similar in both 
treatment groups (39 min for rt-PA alone and 41 min for 
rt-PA plus nitroglycerin). Mean time to infusion of rt-PA 
from the formation of occlusive thrombus was also similar 
(38 min for rt·PA alone, 36 min for rt-PA plus nitroglycerin). 
Administration of rt-PA alone caused reperfusion in 8 of 
11 dogs (reperfusion rate 73%). Mean time to reflow was 
17.6 ± 5.9 min (range 13 to 29). The reestablished blood flow 
was maintained for a 60 min period of observation in only 
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two dogs, with spontaneous reocclusion of the coronary 
artery in the other six (reocclusion rate 75%). Mean duration 
of flow was 42.2 ± 16.0 min (range 17 to 60). Peak coronary 
blood flow in the eight dogs with initial reperfusion was 63 ± 
20 mllmin (range 36 to 90); this amounted to 262 ± 47% 
(range 180% to 318%) of the prethrombus coronary blood 
flow. 
The combination of rt-PA and nitroglycerin caused reper-
fusion in four of seven dogs (reperfusion rate 57%, p = NS 
versus rt-PA alone). However, time to reflow was longer 
(range 20 to 40 min, mean 29.8 ± 9.9) versus rt-PA alone 
(p < 0.02). The reestablished blood flow was maintained for 
37 min in one of the four dogs, but for only 1, 3 and 3 minutes 
in the other three dogs in which reflow occurred (mean 
duration of reflow 11.0 ± 17.4 min, p < 0.02 versus rt-PA 
alone). The peak coronary blood flow in dogs with reperfu-
sion was also lower (range 4 to 118 mllmin, mean 36 ± 52, 
p < 0.02 versus rt-PA alone) and amounted to 156 ± 242% of 
pre thrombus blood flow (p < 0.05 versus rt-PA alone). An 
experiment showing minimal effects of rt-PA when given 
with nitroglycerin is shown in Figure 1. 
In dogs given rt-PA alone or rt-PA plus nitroglycerin, the 
restored blood flow showed fine fluctuation throughout the 
period of reflow, indicative of in vivo platelet aggregation. 
Nitroglycerin also failed to sustain coronary blood flow in all 
four dogs in which it was administered after rt-PA induced 
successful thrombolysis (Fig. 2). 
Effect on systemic hemodynamics (Table 2). Complete 
occlusion of the coronary artery resulted in no change in 
heart rate and a slight decrease in mean arterial pressure. 
Administration ofrt-PA alone resulted in a 7% decrease in 
mean arterial pressure and no change in heart rate. Admin-
istration of nitroglycerin with rt-PA, as expected, caused 
approximately 15% reduction in mean arterial pressure, but 
heart rate was unchanged. 
Plasma t·PA levels. Administration of rt-PA resulted in 
high levels of t-PA in systemic plasma in all dogs. When 
rt-PA was given alone, plasma t-PA levels ranged from 757 
to 2.223 ng/ml (mean 1471 ± 600). In contrast, plasma t-PA 
levels were much lower in dogs given rt-PA with nitroglyc-
erin (range 214 to 800 ng/m!' mean 427 ± 279, p < 0.01). 
Platelet counts and aggregation during thrombosis and 
thrombolysis (Table 3). Platelet counts in peripheral blood 
decreased during thrombus formation in all 18 dogs, and the 
decrease was similar in both groups. During administration 
of rt-PA, reduction in platelet counts stabilized (mean 
change -3 ± 12%, p = NS). In dogs given rt-PA with 
nitroglycerin, platelet counts continued to decrease (mean 
change, -40 ± 23%, P < 0.02 versus change in dogs 
receiving rt-PA alone). 
Whole blood platelet aggregation, measured by imped-
ance aggregometry. also decreased (p < 0.05) after 30 min of 
thrombosis. Platelet aggregation decreased markedly (p < 
0.001) in dogs given rt-PA alone but not in dogs given rt-PA 
with nitroglycerin. In ex vivo experiments, rt·PA exerted a 
concentration-dependent inhibitory effect on whole blood 
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Figure 1. Formation of occlusive thrombus in the left anterior 
descending coronary artery after delivery of continuous anodal 
current. Note the occurrence of zero flow at 30 min (left). In this 
experiment, rt-PA was given with nitroglycerin (NTG). The dose of 
rt-PA was 0.75 mg/kg given over 20 min. Nitroglycerin (125 fLg/min) 
was given concurrently for 40 min. Reperfusion occurred at 35 min, 
but was short-lived (3 min, right). Restoration of coronary blood 
flow (CBF) is seen in both phasic and mean tracings. AP = arterial 
blood pressure. 
platelet aggregation induced by 10 /-LM ADP. The vehicle for 
rt-PA (0.9% NaCl) had no effect on platelet aggregation. 
Total inhibition of platelet aggregation was observed at a 
concentration of 10 /-Lg/ml (Fig. 3). 
Discussion 
Platelets and coronary thrombosis. The coronary throm-
bus formed on delivery of anodal current to the de-
endothelialized arterial surface is due to activation of plate-
lets and their deposition on the intimal surface (20,20. The 
initial platelet thrombus enlarges with incorporation of other 
blood components until blood flow decreases to zero. The 
important role of platelets in coronary thrombosis is appar-
ent from the fluctuations in coronary blood flow before 
development of occlusive thrombus (14,15,28,20,21). Fur-
thermore, dissolution of the thrombus with rt-PA or strep-
tokinase is associated with periodic changes in blood flow, 
similar to those seen in narrowed de-endothelialized canine 
coronary arteries (25,26). The cyclic changes in blood flow 
are believed to be due to platelet accumulation in the 
coronary artery at the site of initial thrombus. Indeed, 
histology of the coronary artery after restoration of flow 
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demonstrates a residual thrombus rich in platelets adherent 
to the intimal surface (21). 
Our observations of a decrease in peripheral blood plate-
let counts during formation of thrombus are further evidence 
for the central role of platelets in thrombus formation (Table 
3). Furthermore, formation of thrombus is delayed when 
thromboxane A2 inhibitors are given before delivery of an 
electric current (23). These agents, when given after resto-
ration of blood flow with thrombolytic agents, reduce sec-
ondary platelet accumulation (14). Thromboxane A2 recep-
tor antagonists also delay or prevent coronary reocclusion 
when given with rt-PA (27,28). Prostacyclin, when adminis-
tered after thrombolysis, also results in improvement in the 
effects of thrombolytic agents (15). In this setting, adminis-
tration of heparin (15) and thrombin inhibitors (16) is also 
beneficial. These observations imply that platelet activation 
is also the basis for coronary reocclusion after initial throm-
bolysis. 
Animal model of coronary thrombus. First we will discuss 
the relevance of this model of canine coronary thrombosis to 
coronary occlusion in acute myocardial ischemia in humans. 
Coronary arteries of patients with acute myocardial infarc-
tion invariably show underlying atherosclerotic obstruction, 
endothelial tear and occlusive thrombus (29). The occlusive 
thrombus always begins with accumulation of platelets at the 
site of endothelial disruption. In the canine model of coro-
nary thrombosis used in this study, histologic examination 
reveals features of human coronary thrombus: endothelial 
disruption and a platelet-rich thrombus formed at the site of 
placement of the external occluder (21). The coronary artery 
is narrowed by placement of an external occluder to mimic 
atherosclerotic narrowing in humans. The presence of an 
external occluder markedly facilitates formation of occlusive 
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thrombus upon delivery of electric current (time to coronary 
occlusion: 20 to 40 min with external narrowing, versus 2 to 
4 h without external narrowing). However, the occluder is 
removed before administration of the thrombolytic regimen 
and stability of the occlusive thrombus is checked over a 
30 min period of administration of saline solution. We (21) 
showed earlier that the frequency of restoration of coronary 
blood flow is markedly improved when the external occluder 
is removed (compared with values when it is left on). 
There are, however, important differences in platelet 
function in dogs and humans; for example, the canine 
platelets are less reactive to aggregatory stimuli than are 
human platelets. Despite the similarities and dissimilarities 
between canine human platelet function and coronary 
thrombus, this model in dogs provides an appropriate 
method for evaluating effects of a variety of thrombolytic 
regimens (14-18, 20-22). 
rt-PA and nitroglycerin and thrombolysis. The dose of 
rt-PA used in these studies (0.75 mg per kg given over 
20 min) is similar to that we (18,21) and other investigators 
(16,17) have used previously. This dose ofrt-PA results in a 
predictable 70% to 75% reperfusion rate, and the reperfused 
artery almost always reoccludes. Therefore, this model is 
suitable for evaluation of pharmacologic agents that may 
influence either the coronary reperfusion rate or reocclusion 
I--- t-PA ---t NTG 
Figure 2. Typical rt-PA-induced thrombolysis (representative of 
four experiments). Administration of nitroglycerin (NTG) does not 
prevent reocclusion of the reperfused coronary artery. Abbrevia-
tions as in Figure I. 
rate, or both. The usual dose of rt-PA in humans is 100 mg, 
of which 60 mg is given in the 1 st h, which is approximately 
1 mg/kg. In this regard the dose of 0.75 mg/kg given over 
20 min in dogs with coronary thrombus is similar to that used 
in humans. We hypothesized that concurrent administration 
of nitroglycerin with rt-PA will enhance the coronary reper-
fusion rate and sustain reperfusion because of its potent 
vasodilator effect. However, nitroglycerin, when given con-
currently with rt-PA, markedly decreased the thrombolytic 
effect of rt-PA. This reduction in efficacy of rt-PA was 
evident from marked prolongation in time to reflow and 
marked reduction in duration of reflow. The magnitude of 
coronary blood flow when restored was also significantly 
less than in dogs given rt-PA with nitroglycerin. 
The coronary artery reoccluded in all dogs given nitro-
glycerin with rt-PA despite continued administration of 
nitroglycerin. The reocclusion rate of 100% was not signifi-
cantly different from the 75% reocclusion rate observed in 
dogs given rt-PA alone. The purpose of continued adminis-
Table 2. Systemic and Myocardial Effects of rt-PA Alone and rt-PA With Nitroglycerin in 18 Dogs With Coronary Thrombosis 
Heart rate (beats/min) 
Mean arterial pressure 
(mmHg) 
Data are mean values ± SO. 
Before 
Thrombus 
153 ± 21 
128 ± 32 
rt-PA Alone (n = II) 
Thrombus 
155 ± 29 
126 ± 30 
During 
rt-PA 
158 ± 26 
117 ± 31 
Before 
Thrombus 
161 ± 24 
122 ± 24 
rt-PA + Nitroglycerin (NTG) (n = 7) 
Thrombus 
162 ± 27 
119 ± 15 
During rt-PA + NTG 
164 ± 22 
100 ± 21 
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Table 3. Effects of rt-PA Alone and rt-PA Plus Nitroglycerin on 
Platelet Counts and Aggregation 
rt-PA Alone rt-PA + 
(n = II) Nitroglycerin (n = 7) 
Platelet counts (X 108/ml) 
Before thrombosis 10.97 ± 2.43 8.30 ± 4.75 
After 30 min of thrombosis 8.77 ± 2.38* 7.27 ± 3.85* 
After rt-PNrt-PA + NTG 7.23 ± 1.68 4.78 ± 3.00' 
Platelet aggregation (0) 
Before thrombosis 6.68 ± 2.16 10.08 ± 4.37 
After 30 min of thrombosis 3.63 ± 1.49* 6.32 ± 7.58* 
After rt-PNrt-PA + NTG 0.23 ± 0.57 5.26 ± 6.23' 
*p < 0.02 versus before thrombosis; tp < 0.02 versus rt-PA alone group. 
Data are mean ± SO. Abbreviations as in Table 2. 
tration of nitroglycerin was to induce sustained coronary 
relaxation, in case coronary vasoconstriction played a role in 
reocclusion after initial reflow. In four dogs, we examined 
the effect of nitroglycerin given after restoration of coronary 
blood flow with rt-PA. In all dogs, the coronary artery 
reoccluded despite continuous nitroglycerin administration 
(Fig. 3). Golino et a1. (30) also found that nitroglycerin failed 
to affect cyclic blood flow changes in narrowed canine 
coronary arteries with endothelial disruption. Taken to-
gether, these observations do not suggest a beneficial effect 
of nitroglycerin on restoration of blood flow in a coronary 
artery with platelet-rich thrombus. 
Reduction in arterial pressure with nitroglycerin. The 
reduction in arterial pressure with nitroglycerin was modest 
and similar in all dogs. We could not derive any relation 
between change in arterial pressure and quality of thrombol-
ysis. One may speculate that a decrease in arterial pressure 
stimulates catecholamine release, which in turn may activate 
platelets. Although this hypothesis cannot be refuted from 
present observations, it is unlikely to be valid because the 
15% reduction in mean arterial pressure observed in dogs 
receiving rt-PA with nitroglycerin usually does not induce 
platelet aggregation. Moreover, platelet aggregation as de-
termined by impedance aggregometry was not increased in 
dogs receiving nitroglycerin with rt-PA. Finally, similar 
blood pressure-lowering doses of prostacyclin given after 
rt-PA-induced thrombolysis generally sustain, rather than 
inhibit, coronary blood flow (15). 
Plasma levels of t·PA with nitroglycerin administration. 
Our study shows that concurrent administration of nitroglyc-
erin with rt-PA causes about a 70% reduction in the circu-
lating levels of t-PA compared with values when rt-PA is 
given alone. The thrombolytic effects of rt-PA in the coro-
nary thrombus model we used are dependent on the dose of 
rt-PA, and therefore it is likely that the relatively lower 
plasma levels oft-PA were the basis for the reduction in the 
quality of thrombolysis when rt-PA was given with nitroglyc-
erin. Although the precise mechanism of the decrease in 
rt-PA levels when nitroglycerin was given concurrently with 
rt-PA is not known, nitroglycerin may have caused an 
increase in hepatic blood flow (31) and facilitated the degra-
I 
time 
f-----I 
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Figure 3. Effect of rt-PA on canine whole blood platelet aggrega-
tion. Note concentration-dependent inhibition of platelet aggrega-
tion by rt-PA. This experiment is typical of three such experiments. 
Control platelet aggregation (rt-PA 0 Itg/ml) was measured using 
0.9% NaCI, solvent for rt-PA. 
dation of rt-PA (32). A similar mechanism of reduction in 
efficacy of rt-PA when given with the prostacyclin analog 
iloprost has also been postulated (17,18). Nitroglycerin may 
have induced a reduction in rt-PA levels by causing vasodi-
lation and subsequent pooling of rt-PA in the peripheral 
circulation (19). 
rt·PA, nitroglycerin and platelet aggregation. We ob-
served a significant inhibitory effect of rt -P A administration 
on the aggregation of canine platelets. The concentration-
dependent inhibitory effects of t-PA on whole blood platelet 
aggregation were also evident in vitro as in previous reports 
(33,34). In contrast, platelet aggregation was not reduced in 
dogs given rt-PA with nitroglycerin. Although nitroglycerin 
has been previously shown to potentiate the platelet inhibi-
tory effects of rt-PA in vitro (34), this was not evident in 
blood taken from dogs given rt-PA with nitroglycerin. Fur-
thermore, platelet sequestration occurring during thrombotic 
occlusion was blocked by rt-PA administration, probably 
due to the restoration of blood flow and due to platelet 
inhibitory concentrations of rt-PA. In contrast, when rt-PA 
was given with nitroglycerin, platelet counts in peripheral 
blood continued to decrease. At the end of rt-PA infusion, 
platelet counts were markedly lower in dogs given rt-PA plus 
nitroglycerin than in those given rt-PA alone. The absence of 
salutary effects on platelet kinetics and platelet aggregation 
function in dogs given rt-PA with nitroglycerin is probably a 
manifestation of the low plasma concentrations of rt-PA in 
these dogs. These observations also indirectly imply that 
platelet inhibition rather than vasospasm is a critical factor in 
the maintenance of patency of the reperfused coronary 
artery. Observations from other laboratories (14-
16,26,27,35) relative to the beneficial effects of thromboxane 
inhibitors. prostacyclin, heparin and thrombin inhibitors are 
also in keeping with this hypothesis. 
Conclusions. Our observations suggest that nitroglycerin 
given concurrently with rt-PA attenuates the thrombolytic 
effects of rt-PA in the canine model of electrically induced 
coronary thrombosis. Nitroglycerin given after rt-PA-
induced thrombolysis does not prevent reocclusion, suggest-
JACC Vol. 17, No.3 
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ing that vasospasm is not an important factor in coronary 
artery reocclusion. 
We thank Janet Wootten and Anne Crawford for their assistance in the 
preparation of this manuscript. 
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